Participants in a prospective, multi-center, randomized, crossover study (NILE – NCT04908254) reported significantly greater adherence to Dayspring treatment, an active compression treatment for lymphedema, in comparison to the use of pneumatic compression pump.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
